INOVIQ (IIQ, formerly BARD1 Life Sciences BD1) is an Australian life sciences company focused on developing and commercialising non-invasive diagnostic tests for early detection of cancer.
Its proprietary technology platform is based on novel tumour markers with potential diagnostic and therapeutic applications across multiple cancers. The pipeline includes two development-stage autoantibody tests for early detection of lung and ovarian cancers, and a research-stage cancer vaccine under evaluation for treatment of cancer.
In July 2020, the company acquired Sienna Cancer Diagnostics and relocated its head office from Perth to Melbourne.
On 9 December 2021, the company changed its name from BARD1 Life Sciences to INOVIQ to represent the company's ‘intelligent innovation’ as it develops and commercialises an innovative portfolio of diagnostic and exosome-based products.
